Actelion close to sealing Ceptaris deal as US approves drug
ZURICH Aug 26 (Reuters) - Swiss biotech firm Actelion said an important condition for its acquisition of privately-held Ceptaris was met with Ceptaris gaining U.S. approval for its Valchlor gel.
The companies are now completing further closing conditions before the acquisition is concluded, Actelion said in a statement on Monday.
The U.S. health regulator FDA has approved Ceptaris Therapeutics' topical drug for treatment of a rare form of non-Hodgkin's lymphoma, Actelion said.
The Allschwil-based company said in July it already paid Ceptaris $25 million and will pay another $225 million when the deal closes.
(Reporting by Alice Baghdjian)
- North Korea's 'reign of terror' worries South's leader
- Los Angeles sheriff's officials charged in jail misconduct probe
- RPT-Record low temperature recorded in Antarctica -scientists
- Google bus blocked in San Francisco gentrification protest
- Putin dissolves state news agency, tightens grip on Russia media